Long-term efficacy of Humalog® in subjects with Type 1 diabetes mellitus

Diabetic Medicine

Volumn 16, Issue 5, 1999, Pages 384-387

  Garg, Satish K ^a,b,d   Anderson, J H ^c   Perry, S V ^a   Mackenziet, T ^b   Keith, P ^c   Jennings, M K ^a   Hansen, M M ^a   Chase, H P ^a,b  

^a UNIVERSITY OF COLORADO DENVER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d NONE   (United States)

Author keywords

Insulin lispro Humalog ; Long term efficacy; Post prandial glucose excursions; Type 1 diabetes mellitus

Indexed keywords

HUMAN INSULIN; INSULIN LISPRO;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENCY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MALE; RANDOMIZED CONTROLLED TRIAL;

ADULT; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; DOUBLE-BLIND METHOD; EATING; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN ANTIBODIES; MALE; POSTPRANDIAL PERIOD; TIME FACTORS;

EID: 0032735368     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-5491.1999.00066.x     Document Type: Article

References (15)

1. 1 The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
2. 2 Chase HP, Jackson WE, Hoops SL, Cockerham RS, Archer PG, O'Brien D. Glucose control and the renal and retinal complications of insulin-dependent diabetes. J Am Med Assoc 1989; 261: 1155-1160.
3. 3 Bhaskar R, Chou MCY, Field JB. Time-action characteristics of Human soluble and NPH insulin in insulin-treated diabetics. J Clin Endocrinol Metab 1980; 50: 475-479.
4. 4 Gardner DF, Arakaki RF, Podet EJ, Nell LJ, Thomas JW, Field JB. The pharmacokinetics of subcutaneous human soluble insulin in type 1 diabetic patients: assessment using a glucose clamp technique. J Clin Endocrinol Metab 1986; 63: 689-694.
5. 5 Howey DC, Bowsher RR, Brunelle RL, Woodworth JR. [Lys(B28)-Pro(B29)]-human insulin: a rapidly absorbed analogue of human insulin. Diabetes 1994; 43: 396-402.
6. 6 Howey DC, Bowsher RR, Brunelle RL, Rowe HM, Santa PF, Downing-Shelton J et al. [Lys(B28), Pro(B29)]-human insulin: effect of injection time on post-prandial glycaemia. Clin Pharmacol Ther 1995; 58: 459-469.
7. 7 Galloway JA, Chance RE. Diabetes Annual #8: Approaches to Insulin Analogues. Amsterdam: Elsevier Science Publishers, 1994; 277-297.
8. 8 Torlone E, Fanelli C, Rambotti AM, Kassi G, Modarelli F, DiVincenzo A et al. Pharmacokinetics, pharmacodynamics, and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys (B28), Pro(B29)] in IDDM. Diabetologia 1994; 37: 713-720.
9. 9 Brems DN, Brown PL, Bryant C, Chance RE, Green LK, Long HB et al. Altering the association properties of insulin by amino acid replacement. Protein Eng 1992; 5: 527-533.
10. 10 Garg SK, Carmain JA, Braddy KC, Anderson JH, Vignati L, Jennings MK et al. Pre-meal insulin analogue insulin-lispro vs. Humulin® R insulin treatment in young subjects with Type 1 diabetes. Diabetic AW 1996; 13: 47-52.
11. 11 Anderson JH, Brunelle RL, Koivisto VA, Pfitzner A, Trautmann ME, Vignati L et al. The Multicenter Insulin Lispro Study Group: Reduction of post-prandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Diabetes 1997; 46: 265-270.
12. 12 Rutledge KS, Chase HP, Klingensmith GJ, Walravens PA, Slover RH, Garg SK. Effectiveness of post-prandial Humalog® in toddlers with diabetes. Pediatrics 1997; 100: 968-972.
13. 13 Fineberg NS, Fineberg SE, Anderson JH, Birkett MA, Gibson RG, Hufferd S. Immunologic effects of insulin lispro [Lys(B28), Pro(B29) human insulin] in IDDM and NIDDM patients previously treated with insulin. Diabetes 1996; 45: 1750-1754.
14. 14 ProcGLM, SAS System 6 12 for Windows. Cary, NC: SAS Institute, Inc., 1996.
15. 15 Chase HP, Garg SK. At the controls: Lispro. Diabetes Forecast 1997; 35: 32-39.